
    
      METHODOLOGY:

      The present study is a multicenter, open-label, non-controlled, phase II study in patients
      who are suffering from recurrent and/or metastatic Salivary Glands Carcinoma, who have
      progressed during the 6 months period before entering the study and who are eligible for
      nivolumab monotherapy.

      All eligible patients will receive nivolumab treatment for a maximum of 12 cycles of
      treatment. 92 eligible patients will be dosed with nivolumab intravenously over 60 minutes (Â±
      5 minutes) at 3 mg/kg every two weeks.

      Each 28-day dosing period will constitute a cycle.
    
  